Olipudase Alfa: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 941, doi. 10.1007/s40265-022-01727-x
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 8
Results: 9
1
2
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 865, doi. 10.1007/s40265-022-01726-y
- By:
- Publication type:
- Article
3
Delafloxacin: A Review in Community-Acquired Pneumonia.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 913, doi. 10.1007/s40265-022-01725-z
- By:
- Publication type:
- Article
4
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 889, doi. 10.1007/s40265-022-01728-w
- By:
- Publication type:
- Article
5
Delafloxacin: A Review in Community-Acquired Pneumonia.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 913, doi. 10.1007/s40265-022-01725-z
- By:
- Publication type:
- Article
6
Ganaxolone: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 933, doi. 10.1007/s40265-022-01724-0
- By:
- Publication type:
- Article
7
Nivolumab Plus Relatlimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 925, doi. 10.1007/s40265-022-01723-1
- By:
- Publication type:
- Article
8
New Topical Therapies in Development for Atopic Dermatitis.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 843, doi. 10.1007/s40265-022-01722-2
- By:
- Publication type:
- Article
9
Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 855, doi. 10.1007/s40265-022-01721-3
- By:
- Publication type:
- Article